Health
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD).","length":517,"tagName":"p"},{"type":"text","content":"If approved, orphan drug designation will qualify NanoViricides for incentives including:","length":89,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Tax credits for qualified clinical trials;","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Exemption from certain user fees;","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential seven years of market exclusivity after approval;","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":134,"olType":false},{"type":"text","content":"According to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products).","length":158,"tagName":"p"},{"type":"text","content":""NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R. Diwan, PhD, adding, "Treating a patient and providing the drug prophylactically to contacts would eliminate the need for quarantine and loss of valuable school time. An Orphan Drug Designation would help us tremendously in the mission of regulatory development and approval of NV-387 to treat Measles."","length":462,"tagName":"p"},{"type":"text","content":"Measles cases have been rising in the USA reaching 2,251 confirmed cases with 3 deaths in 2025, from 285 in 2024 and 59 in 2023 (no deaths in these prior years). As of February 5, 2026, already 727 confirmed measles cases were reported in the United States in 2026. Vaccine breakthrough accounted for 6-7% of cases, with the remaining cases being in unvaccinated or persons with unknown vaccine status (https://www.cdc.gov/measles/data-research/index.html). Measles continues to be a rare disease in the...